AbbVie submits EMA regulatory application for SKYRIZI Crohn’s induction
AbbVie submitted a regulatory application to the EMA for SKYRIZI subcutaneous induction in adults with moderately to severely active Crohn’s disease.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.